Itraconazole (200 mg)
Sponsors
H. Lundbeck A/S, Lomond Therapeutics Holdings, Inc., Immunome, Inc., Urooj Fatima, Pak Emirates Military Hospital
Conditions
AMLCytochrome P450 InteractionDermatophytosisHealthyHealthy VolunteerTinea Corporis
Phase 1
Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women
CompletedNCT03103646
Start: 2017-03-28End: 2019-07-19Updated: 2019-10-02
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
CompletedNCT06399315
Start: 2023-07-28End: 2025-08-26Updated: 2025-12-09
A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants
CompletedNCT06677996
Start: 2024-11-11End: 2025-05-07Updated: 2025-05-11
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
CompletedNCT06787131
Start: 2024-05-21End: 2025-07-04Updated: 2025-12-05
Phase 4
Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis
RecruitingNCT07342153
Start: 2025-11-01End: 2026-03-10Target: 126Updated: 2026-01-15
Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety a n d Cure Rate in Adult Patients of Tinea Corporis/ Cruris-A Randomised Controlled Trail
Not yet recruitingNCT07675239
Start: 2026-10-01End: 2027-03-01Target: 60Updated: 2026-06-30